April 18, 2014 7:21 PM ET


Company Overview of Cardioxyl Pharmaceuticals, Inc.

Company Overview

Cardioxyl Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies and technologies for the treatment of cardiovascular diseases. It offers nitroxyl therapeutics, including CXL-1020, a nitroxyl donor compound for the intravenous treatment of acute decompensated heart failure; and nitroxyl donor compounds for unmet medical needs in other cardiovascular indications. The company was founded in 2005 and is based in Chapel Hill, North Carolina.

1450 Raleigh Road

Exchange East

Suite 212

Chapel Hill, NC 27517-8833

United States

Founded in 2005





Key Executives for Cardioxyl Pharmaceuticals, Inc.

Chief Executive Officer
Scientific Co-Founder and Member of Scientific Advisory Board
Scientific Co-Founder
Scientific Co-Founder and Member of Scientific Advisory Board
Founder and Senior Vice President of Chemistry & Pre-Clinical Development
Compensation as of Fiscal Year 2013.

Cardioxyl Pharmaceuticals, Inc. Key Developments

Cardioxyl Pharmaceuticals, Inc. Initiates First Clinical Trial of CXL-1427

Cardioxyl Pharmaceuticals, Inc. announced that the first cohort of patients has been dosed in a Phase I clinical trial of CXL-1427, a novel nitroxyl (HNO) prodrug optimized for clinical development as a potential treatment for acute decompensated heart failure (ADHF). The primary objective of the Phase 1 clinical trial is to evaluate the safety and tolerability of continuous intravenous infusions of CXL-1427 for up to 48-hours in healthy volunteers. This Phase I trial of CXL-1427, which is set to be conducted over the first half of 2014, is a randomized, double-blind, placebo-controlled ascending dose evaluation of CXL-1427 in healthy volunteers. The study will enroll up to a total of 110 subjects and will evaluate the safety and pharmacokinetics of 24- and 48-hour infusions of CXL-1427. Pending successful completion of this Phase 1 trial, Cardioxyl anticipates initiating subsequent trials of CXL-1427 in patients with acute decompensated heart failure.

Cardioxyl Pharmaceuticals, Inc. Appoints Shi Yin Foo as Chief Medical Officer

Cardioxyl Pharmaceuticals, Inc. announced the appointment of Shi Yin Foo, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Foo, who has broad experience in the development of cardiovascular drugs and translational medicine, is well positioned to help Cardioxyl realize the potential of its nitroxyl (HNO) technology for the treatment of patients with serious cardiovascular disease. Dr. Foo joins Cardioxyl from Novartis, where she was responsible for the establishment and execution of multiple novel programs in heart failure and the cardiorenal space, and is a named inventor on several associated patents applications.

Similar Private Companies By Industry

Company Name Region
Spero Therapeutics United States
7 Oaks Pharmaceutical Corp. United States
CreoSalus, Inc. United States
Zurex Pharma, Inc. United States
Akrimax Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cardioxyl Pharmaceuticals, Inc., please visit www.cardioxyl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.